NCT03260491
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 53 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 90 words Show 6 more changesShow less
- Primary completion date changed from estimate of Mar 31, 2026 to Dec 1, 2025
- Study completion pushed from Dec 31, 2026 to Jul 30, 2027
- Secondary endpoints: details revised at 1 of 23 entries
- Site details revised at 3 of 37 sites
- Collaborators: details revised at 1 of 1 entry
- Study description expanded, about 3 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 309 to confirmed 312
- Site details revised at 37 of 37 sites
- Minor Site details revised at 1 of 37 sitesv51
- Minor Study sites: 36 to 37v50
- Minor Site details revised at 8 of 36 sitesv49
Show 29 earlier versionsHide 29 earlier versions
Notable Eligibility criteria expanded, about 26 wordsv48 Show 4 more changesShow less
- Primary endpoints revised (5)
- Study sites: 22 to 36
- Secondary endpoints revised (23)
- Study title revised
- Study Status, Sponsor/Collaboratorsv47
- Minor Secondary endpoints revised (23)v46
Notable Trial status: Active, Not Recruiting to Recruitingv45 Show 11 more changesShow less
- Primary completion date: Jan 28, 2022 to Mar 31, 2026
- Eligibility criteria expanded, about 866 words
- Primary endpoints revised (5)
- Enrollment target: 271 to 309
- Study sites: 20 to 22
- Study completion date: Dec 31, 2024 to Dec 31, 2026
- Interventions: U3-1402 (CTM-1 Lyo-DP) (Drug), U3-1402 (CTM-3 Lyo-DP) (Drug), U3-1402 (FL-DP) (Drug) to HER3-DXd (CTM-1 Lyo-DP) (Drug), HER3-DXd (CTM-3 Lyo-DP) (Drug), HER3-DXd (FL-DP) (Drug)
- Secondary endpoints: 28 to 23
- Study description expanded, about 29 words
- Study title revised
- Study arms: 9 to 10
- Minor Study completion date: Dec 31, 2023 to Dec 31, 2024v44
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 264 to confirmed 271
- Study sites: 22 to 20
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary endpoints revised (5)
- Study sites: 20 to 22
- Secondary endpoints: 27 to 28
- Minor Enrollment target: 216 to 264v41
Notable Eligibility criteria expanded, about 150 wordsv40 Show 5 more changesShow less
- Primary endpoints: 3 to 5
- Study completion date: Nov 1, 2023 to Dec 31, 2023
- Interventions: U3-1402 (Drug) to U3-1402 (CTM-1 Lyo-DP) (Drug), U3-1402 (CTM-3 Lyo-DP) (Drug), U3-1402 (FL-DP) (Drug)
- Secondary endpoints revised (27)
- Study arms: 8 to 9
- Minor Primary completion date changed from estimate of Dec 31, 2021 to Jan 28, 2022
- Study completion date: Dec 31, 2023 to Nov 1, 2023
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 22 to 20
- Minor Site details revised at 1 of 22 sitesv28
- Minor Site details revised at 1 of 22 sitesv27
- Minor Site details revised at 2 of 22 sitesv26
- Minor Study sites: 20 to 22v25
- Minor Study sites: 18 to 20v24
- Minor Study sites: 14 to 18v23
Notable Eligibility criteria expanded, about 32 wordsv22 Show 5 more changesShow less
- Primary endpoints revised (3)
- Enrollment target: 198 to 216
- Primary completion date: Oct 31, 2021 to Dec 31, 2021
- Study completion date: Oct 31, 2023 to Dec 31, 2023
- Secondary endpoints: 31 to 27
- Minor Study sites: 12 to 14v21
- Notable Primary endpoints revised (3)
- Eligibility criteria expanded, about 3 words
- Notable Enrollment target: 130 to 198
- Eligibility criteria shortened, about 10 words
- Study sites: 11 to 12
- Study arms: 1 to 8
- Minor Study sites: 10 to 11v14
- Minor Study sites: 7 to 10v13
- Minor Study sites: 5 to 7v12
- Notable Eligibility criteria expanded, about 9 words
- Study sites: 4 to 5
- Notable Enrollment target: 63 to 130
- Primary completion date: Feb 28, 2020 to Oct 31, 2021
- Study completion date: Feb 28, 2020 to Oct 31, 2023
- Minor Site details revised at 1 of 4 sitesv7
- Minor Study sites revised (4)v5
- Study Status, Contacts/Locationsv4
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (23)
Show 18 moreShow less
Arms and interventions
Participants in the Dose Escalation Cohort 1 will receive HER3-DXd intravenously (IV) once every three weeks at 3.2 mg/kg.
Participants in Dose Escalation Cohort 2 will receive HER3-DXd intravenously (IV) once every three weeks at 4.8 mg/kg.
Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 5.6 mg/kg.
Participants in Dose Escalation Cohort 3 will receive HER3-DXd intravenously (IV) once every three weeks at 6.4 mg/kg.
Participants with adenocarcinoma NSCLC with EGFR mutations in the Dose Expansion Cohort 1 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).
Participants with squamous or non-squamous NSCLC without EGFR-activating mutations in the Dose Expansion Cohort 2 will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE).
Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3a will receive HER3-DXd IV once every three weeks at the established recommended dose for expansion (RDE) or, if applicable, adjusted RDE (aRDE).
Randomized participants with NSCLC and EGFR mutations in the Dose Expansion Cohort 3b will receive HER3-DXd IV once every three weeks following an up-titration regimen (Cycle 1, Day 1: 57% of RDE or aRDE; Cycle 2, Day 1: 86% of RDE or, if applicable aRDE; Cycle 3 and subsequent cycles, Day 1: 114% of RDE or aRDE).
Participants with NSCLC (including any histology other than small-cell or combined small-cell and non-small cell) with an EGFR-activating mutation will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.
Participants with locally advanced or metastatic NSCLC whose tumors harbor a KRAS-G12C mutation and that have progressed on the most recent line of therapy will receive HER3-DXd IV at 5.6 mg/kg every 3 weeks.
Drugs: HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Sites
37 sites in 6 countries
United States 16, Spain 9, Japan 5, South Korea 3, Taiwan 3, Netherlands 1